Literature DB >> 12822818

Epilepsy in neurofibromatosis 1.

Rossella Vivarelli1, Salvatore Grosso, Fulvia Calabrese, MariaAngela Farnetani, Rosanna Di Bartolo, Guido Morgese, Paolo Balestri.   

Abstract

Neurofibromatosis 1 is the most common neurocutaneous disease. Neurologic manifestations are mainly represented by tumors such as optic gliomas, focal areas of high T2-weighted signal known as unidentified bright objects, and mental retardation or learning disabilities. The prevalence of seizures has been reported to range from 3.8 to 6%. In the present study, we evaluated prevalence, type, and etiology of epilepsy in a neurofibromatosis 1 population. A retrospective analysis of 198 patients affected by neurofibromatosis 1 was performed. Fourteen patients (7%) were found to be epileptic. Every patient underwent electroencephalographic examination and neuroimaging investigations. Thirteen were submitted to magnetic resonance imaging (MRI) study and one to computed tomographic (CT) scanning. Single-photon emission computed tomographic and positron emission tomographic studies were performed in a few selected cases. Seizures were partial in 12 of these (85%) and generalized in 2 (15%). In nine (64%), epilepsy was secondary to brain lesions: five of these had cerebral tumors (three with epilepsy as the fist symptom), three had cortical malformation, and one had mesial temporal sclerosis. Seizures were controlled rapidly in eight (57%) and drug resistant in four (29%). Two patients were lost at follow-up. All patients with uncontrolled seizures had severe mental retardation, and three of these had malformations of cortical development. Our observations and our re-evaluation of the literature indicate that patients with neurofibromatosis 1 have an increased risk of epilepsy related to intracranial masses and cytoarchitectural abnormalities, and seizures can represent the first symptom of a tumor or cortical malformation. Brain MRI and, in selected cases, functional studies appear to be useful in patients with neurofibromatosis 1 who present with seizures, especially if associated with mental retardation.

Entities:  

Mesh:

Year:  2003        PMID: 12822818     DOI: 10.1177/08830738030180050501

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  17 in total

1.  Neurofibromatosis type 1 and infantile spasms.

Authors:  Martino Ruggieri; Paola Iannetti; Maurizio Clementi; Agata Polizzi; Gemma Incorpora; Alberto Spalice; Piero Pavone; Andrea Domenico Praticò; Maurizio Elia; Anna Lia Gabriele; Romano Tenconi; Lorenzo Pavone
Journal:  Childs Nerv Syst       Date:  2008-09-19       Impact factor: 1.475

2.  Therapeutics for childhood neurofibromatosis type 1 and type 2.

Authors:  Simone L Ardern-Holmes; Kathryn N North
Journal:  Curr Treat Options Neurol       Date:  2011-12       Impact factor: 3.598

3.  Epilepsy in NF1: a systematic review of the literature.

Authors:  Pia Bernardo; Giuseppe Cinalli; Claudia Santoro
Journal:  Childs Nerv Syst       Date:  2020-07-01       Impact factor: 1.475

Review 4.  Guidelines for the diagnosis and management of individuals with neurofibromatosis 1.

Authors:  Rosalie E Ferner; Susan M Huson; Nick Thomas; Celia Moss; Harry Willshaw; D Gareth Evans; Meena Upadhyaya; Richard Towers; Michael Gleeson; Christine Steiger; Amanda Kirby
Journal:  J Med Genet       Date:  2006-11-14       Impact factor: 6.318

Review 5.  Hippocampal sclerosis and epilepsy surgery in neurofibromatosis type 1: case report of a 3-year-old child explored by SEEG and review of the literature.

Authors:  Claudine Sculier; Delphine Taussig; Alec Aeby; Jerry Blustajn; Olivier Bekaert; Martine Fohlen
Journal:  Childs Nerv Syst       Date:  2021-09-10       Impact factor: 1.532

Review 6.  The Role of Transposable Elements of the Human Genome in Neuronal Function and Pathology.

Authors:  Ekaterina Chesnokova; Alexander Beletskiy; Peter Kolosov
Journal:  Int J Mol Sci       Date:  2022-05-23       Impact factor: 6.208

7.  Spred1, a negative regulator of Ras-MAPK-ERK, is enriched in CNS germinal zones, dampens NSC proliferation, and maintains ventricular zone structure.

Authors:  Timothy N Phoenix; Sally Temple
Journal:  Genes Dev       Date:  2010-01-01       Impact factor: 11.361

8.  Seizure, spinal schwannoma, peripheral neuropathy and pulmonary stenosis - A rare combination in a patient of Neurofibromatosis 1.

Authors:  Avas Chandra Ray; Nabendu Karjyi; Achintya Narayan Roy; Arup Kumar Dutta; Atanu Biswas
Journal:  Ann Indian Acad Neurol       Date:  2012-01       Impact factor: 1.383

9.  Neurofibromatosis type 1 and chronic neurological conditions in the United States: an administrative claims analysis.

Authors:  Chinwe C Madubata; Margaret A Olsen; Dustin L Stwalley; David H Gutmann; Kimberly J Johnson
Journal:  Genet Med       Date:  2014-06-05       Impact factor: 8.822

10.  A Potential Role for Felbamate in TSC- and NF1-Related Epilepsy: A Case Report and Review of the Literature.

Authors:  Natanya M Mishal; Dimitrios Arkilo; Ju Tang; John R Crawford; Sonya G Wang
Journal:  Case Rep Neurol Med       Date:  2015-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.